This CME program is derived from content presented at the 2024 Eastern Pulmonary Conference. The expert faculty, Dr. Samantha Gillenwater, will first review emerging therapeutics for pulmonary arterial hypertension (PAH). Following, she will analyze the clinical trial data and clinical applications for activin signaling inhibitor therapeutics, targeting higher risk patients with PAH. Lastly, Dr. Gillenwater will discuss specific considerations for underserved populations and how to effectively engage in collaboration with the healthcare team for optimal treatment of patients with pulmonary arterial hypertension.
Pulmonologists, Primary Care Practitioners, APPs, and other healthcare professionals involved in the treatment and management of patients with PAH
Review emerging therapeutics for PAH, including the mode of action for activin signaling inhibitors
Analyze clinical trial data and clinical applications for activin signaling inhibitor therapeutics targeting higher risk patients with PAH
Recognize specific considerations for underserved populations and effectively engage in collaboration with the healthcare team for optimal treatment of patients with PAH
Update for Activin Signaling Inhibitors and Newer Therapeutics for the Management of Patients with PAH
Clinical Trial Analysis for Activin Signaling Inhibitors for the Treatment of PAH
Practical Considerations for Managing PAH: Early Intervention, Patient Education, Shared Decision Making and Addressing the Needs of Diverse Patient Populations
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Samantha Gillenwater, MD | Speaker: Janssen Global Services, LLC |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Merck & Co., Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606